[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2019 - April 2016

Decade

Year

Issue

July 2019, Vol 4, No. 7, Pages 607-714

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):607. doi:10.1001/jamacardio.2018.3205
Original Investigation

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial

Abstract Full Text
JAMA Cardiol. 2019;4(7):613-619. doi:10.1001/jamacardio.2019.0886

This prespecified analysis of a randomized clinical trial evaluates the effect of evolocumab on total cardiovascular events.

Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):620-627. doi:10.1001/jamacardio.2019.1581

This study combines data from multiple cohorts to assess the association of LPA variants with calcific aortic valve stenosis in patients undergoing heart surgery, patients with coronary artery disease, first-degree relatives of patients with coronary artery disease, and unrelated control participants.

Association of Conventional Cardiovascular Risk Factors With Cardiovascular Disease After Hypertensive Disorders of Pregnancy: Analysis of the Nord-Trøndelag Health Study

Abstract Full Text
open access
JAMA Cardiol. 2019;4(7):628-635. doi:10.1001/jamacardio.2019.1746

This cohort study examines the excess risk of cardiovascular disease in women with a history of hypertensive disorders of pregnancy and estimates the proportion associated with conventional cardiovascular risk factors.

Association of Dimethylguanidino Valeric Acid With Partial Resistance to Metabolic Health Benefits of Regular Exercise

Abstract Full Text
JAMA Cardiol. 2019;4(7):636-643. doi:10.1001/jamacardio.2019.1573

This cross-sectional analysis of an endurance exercise trial investigates the associations between dimethylguanidino valeric acid levels and metabolic health traits before and after 20 weeks of endurance exercise training.

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):644-657. doi:10.1001/jamacardio.2019.1391

This cohort study assesses the reliability of sudden cardiac death prediction methods leading to prophylactic implantable cardioverter/defibrillator recommendations to reduce the number of sudden cardiac deaths occurring in patients with hypertrophic cardiomyopathy.

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial

Abstract Full Text
JAMA Cardiol. 2019;4(7):659-669. doi:10.1001/jamacardio.2019.1776

This prespecified analysis of a randomized clinical trial assesses the outcome of all-comer patients with small coronary vessel lesions treated with 3 dissimilar types of drug-eluting stents.

Association of Medicaid Expansion With Cardiovascular Mortality

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):671-679. doi:10.1001/jamacardio.2019.1651

This difference-in-differences analysis investigates the association of Medicaid expansion with cardiovascular mortality rates for middle-aged adults using data from 48 states and Washington, DC.

Brief Report

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes

Abstract Full Text
JAMA Cardiol. 2019;4(7):680-684. doi:10.1001/jamacardio.2019.1510

This study investigates whether mandatory reporting of CYP2C19 metabolizer status influence physicians’ decisions to switch P2Y12 inhibitors in the context of a clinical trial.

Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors

Abstract Full Text
has audio
JAMA Cardiol. 2019;4(7):685-689. doi:10.1001/jamacardio.2019.1518

This cohort study uses data from a large blood donation program to estimate the prevalence of familial hypercholesterolemia in a population of more than 1 million individual donors with a total of more than 3 million blood donations.

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease

Abstract Full Text
open access
JAMA Cardiol. 2019;4(7):691-695. doi:10.1001/jamacardio.2019.1647

This economic analysis uses an updated cost-effectiveness analysis of evolocumab added to standard therapy in patients with very high-risk atherosclerotic cardiovascular disease, reflecting new guidelines and a new evolocumab list price.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies

Abstract Full Text
JAMA Cardiol. 2019;4(7):696-701. doi:10.1001/jamacardio.2019.1739

This analysis of data from the DEFINE-HF and BIOSTAT-CHF cohort studies defines and describes similarities and differences between iron deficiency due to low iron storage and defective iron utilization in patients with heart failure.

Viewpoint

Heart Failure, Shared Decision-making, and Social Determinants of Health: An Upstream Perspective

Abstract Full Text
JAMA Cardiol. 2019;4(7):609-610. doi:10.1001/jamacardio.2019.1763

This Viewpoint discusses the influence social determinants of health have on shared decision-making between patients and clinicians regarding heart failure.

From the Heart

A Change of Heart

Abstract Full Text
JAMA Cardiol. 2019;4(7):611-612. doi:10.1001/jamacardio.2019.1197

This essay describes a physician’s experience with making alterations to a patient’s do-not-resuscitate order.

Invited Commentary

Sudden Cardiac Death Risk in Hypertrophic Cardiomyopathy: Wither Our Cognitive Miser

Abstract Full Text
JAMA Cardiol. 2019;4(7):657-658. doi:10.1001/jamacardio.2019.1438

Screening for Familial Hypercholesterolemia

Abstract Full Text
has audio
JAMA Cardiol. 2019;4(7):689-690. doi:10.1001/jamacardio.2019.1509
Review

Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review

Abstract Full Text
has active quiz
JAMA Cardiol. 2019;4(7):702-707. doi:10.1001/jamacardio.2019.1176

This narrative review summarizes the findings of clinical trials that assess the value of losartan plus β-blockers vs either drug alone to prevent aortic dissections in patients with Marfan syndrome.

JAMA Cardiology Clinical Challenge

A Woman With Multiparity Experiencing Chest Pain in Her Early 60s

Abstract Full Text
has active quiz
JAMA Cardiol. 2019;4(7):710-711. doi:10.1001/jamacardio.2018.4511

A woman in her early 60s with a history of hypertension, dyslipidemia, multiparity, and coronary angiogram 1 year prior presents with sudden onset of severe chest pain not alleviated by changing position and radiating to the left arm with concomitant nausea and diaphoresis. What would you do next?

JAMA Cardiology Clinical Guidelines Synopsis

Evaluation and Treatment of Patients With Bradycardia and Cardiac Conduction Delay

Abstract Full Text
JAMA Cardiol. 2019;4(7):708-709. doi:10.1001/jamacardio.2019.1069

This article describes the 2018 American College of Cardiology, American Heart Association, and Heart Rhythm Society Guideline on Bradycardia and Conduction Delay for patients who may need permanent pacing.

Comment & Response

Risks of High Coronary Artery Calcium

Abstract Full Text
JAMA Cardiol. 2019;4(7):712. doi:10.1001/jamacardio.2019.1400

Risks of High Coronary Artery Calcium

Abstract Full Text
JAMA Cardiol. 2019;4(7):712-713. doi:10.1001/jamacardio.2019.1403

Risks of High Coronary Artery Calcium—Reply

Abstract Full Text
JAMA Cardiol. 2019;4(7):713. doi:10.1001/jamacardio.2019.1406

A Myocardial Bridge or Not?

Abstract Full Text
JAMA Cardiol. 2019;4(7):713-714. doi:10.1001/jamacardio.2019.1658

A Myocardial Bridge or Not?—Reply

Abstract Full Text
JAMA Cardiol. 2019;4(7):714. doi:10.1001/jamacardio.2019.1664
Editor's Note

When Can Strut Thickness Really Matter in Percutaneous Coronary Intervention?

Abstract Full Text
JAMA Cardiol. 2019;4(7):669-670. doi:10.1001/jamacardio.2019.1902
Correction

Error in Figure

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):714. doi:10.1001/jamacardio.2019.2415

Error in Author Affiliations

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):714. doi:10.1001/jamacardio.2019.2553
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2019;4(7):608. doi:10.1001/jamacardio.2018.3206
×